Exenatide enhances kaliuresis under conditions of hyperkalemia.
Bull Exp Biol Med · 2011
Last updated 2026-05-28In rats, the drug exenatide increased potassium excretion in urine from 7 to 16 micromoles per hour when potassium levels were normal. Under conditions of high potassium (hyperkalemia), exenatide doubled potassium excretion to 97 micromoles per hour compared to 47 micromoles per hour without the drug.
AI summary of the abstract below.
| Journal | Bull Exp Biol Med, 2011 |
|---|---|
| Citations | 3 |
| Relative citation ratio | 0.07 |
| NIH percentile | 6 |
| Molecules | exenatide |
Abstract
Experiments on Wistar rats showed that exenatide (0.015-0.5 nmol per 100 g body weight) somewhat increased renal excretion of potassium from 7±1 to 16±1 μmol/h/100 g body weight (p<0.05) in animals with normal serum concentration of glucose (4.6±0.4 mM) and potassium (4.3±0.1 mM). Exenatide dramatically enhanced excretion of potassium under conditions of hyperkalemia (11.4±0.4 mM) produced by intraperitoneal injection of 1.25% KCl solution (5 ml per 100 g body weight). During the first postinjection hour, potassium excretion increased 2-fold and attained 97±11 μmol/h/100 g body weight in comparison with potassium load alone (47±9 μmol/h/100 g body weight, p<0.05). The data attest to a possible role of peptide regulators in normalization of potassium balance via renal mechanisms.
Verbatim abstract via PubMed 22808453 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.